TOP > 外国特許検索 > METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA NEW

外国特許コード F170009258
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP072204
国際公開番号 WO 2017022634
国際出願日 平成28年7月28日(2016.7.28)
国際公開日 平成29年2月9日(2017.2.9)
優先権データ
  • 特願2015-151838 (2015.7.31) JP
発明の名称 (英語) METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA NEW
発明の概要(英語) [Problem] The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma. [Solution] The present invention relates to a method for evaluating the prognosis of glioma, said method comprising the steps of: detecting ACTC1 protein and/or mRNA encoding the protein in a glioma-containing sample collected from a patient; and determining that the prognosis of the glioma is poor when the ACTC1 protein and/or the mRNA encoding the protein is detected in the aforementioned step. According to the present invention, the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability and the like can be evaluated using a novel biomarker, i.e., ACTC1 protein and/or mRNA encoding the protein.
特許請求の範囲(英語) [claim1]
1. The ACTC1 protein in the sample which includes [gurioma] which was picked from the patient and/or this the cord/code the process which detects mRNA which is done, and
When the ACTC1 protein and/or this the cord/code mRNA which is done is detected in the aforementioned process, as for aforementioned [gurioma] the process which it decides that it is convalescence defective,
The method of including, deciding the convalescence of [gurioma].
[claim2]
2. The ACTC1 protein in the sample which includes [gurioma] which was picked from the patient and/or this the cord/code the process which detects mRNA which is done, and
When the ACTC1 protein and/or this the cord/code mRNA which is done is detected in the aforementioned process, as for aforementioned [gurioma] the process which it decides that risk of remote section recurrence is high,
The method of including, deciding the remote section recurrence risk of [gurioma].
[claim3]
3. The ACTC1 protein in the sample which includes the [gurioma] cell and/or this the cord/code the process which detects mRNA which is done, and
When the ACTC1 protein and/or this the cord/code mRNA which is done is detected in the aforementioned process, as for the aforementioned [gurioma] cell the process which it decides that infiltration talent is high,
The method of including, deciding the infiltration talent of the [gurioma] cell.
[claim4]
4. The ACTC1 protein in the sample which was picked from the [gurioma] lesion section or the vicinity of the patient and/or this the cord/code the process which detects mRNA which is done, and
When the ACTC1 protein and/or this the cord/code mRNA which is done is detected in the aforementioned process, the process which it decides that [gurioma] whose infiltration talent is high is included in the aforementioned sample,
It includes, the method of deciding the existence of [gurioma] whose infiltration talent in the aforementioned sample is high.
[claim5]
5. The ACTC1 protein in the sample which includes [gurioma] which was picked from the patient and/or this the cord/code the expedient which detects mRNA which is done is included, convalescence of [gurioma] and/or the kit in order to decide remote section recurrence risk.
[claim6]
6. The kit in order the ACTC1 protein in the sample which includes the [gurioma] cell and/or this the cord/code includes the expedient which detects mRNA which is done, to decide the infiltration talent of the [gurioma] cell.
[claim7]
7. The ACTC1 protein in the sample which was picked from the [gurioma] lesion section or the vicinity of the patient and/or this the cord/code the expedient which detects mRNA which is done is included, the kit in order to decide the existence of [gurioma] whose infiltration talent in the aforementioned sample is high.
[claim8]
8. Either the primer nuclear acid or probe nuclear acid in order to detect mRNA which unique antibody or ACTC1 in order to detect the ACTC1 protein the cord/code is done is included at least, from claim 5 in either of 7 the kit of statement.
[claim9]
9. The medicine composition in order revelation of the ACTC1 to deal with protein and/or includes the substance which controls function, [gurioma].
[claim10]
10. Revelation of the ACTC1 protein and/or the substance which controls function, is the obstruction characteristic nuclear acid for the gene which the ACTC1 protein the cord/code is done, in claim 9 the medicine composition of statement.
[claim11]
11. The obstruction characteristic nuclear acid for the gene which the ACTC1 protein the cord/code is done it is the revelation possible rearrangement virus, in claim 9 or 10 the medicine composition of statement.
[claim12]
12. Revelation of the ACTC1 protein and/or the substance which controls function, is the neutralizing antibody for the ACTC1 protein, in claim 9 the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • HONMOU OSAMU
  • WANIBUCHI MASAHIKO
  • OHTAKI SHUNYA
  • SASAKI MASANORI
  • SASAKI YUKO
  • MIKUNI NOBUHIRO
国際特許分類(IPC)
指定国 (WO201722634)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close